Several studies had successfully converted by infusing TSCM cells derived from circulating CD8+ T cells, and it showed robust cellular immune responses in the treatment of different cancers such as non-small cell lung cancer, acute myeloid leukemia and renal cell carcinoma (257–259). The gene discussed is CD8A; the disease is cancer.